Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
HB484 creates a new corporate income tax addition modification for certain direct-to-consumer advertising expenses related to covered prescription drugs and compounded drugs. In practical terms, if a corporation deducts these advertising costs under federal tax law, Maryland would require those amounts to be added back when calculating Maryland modified income, increasing the corporation’s Maryland taxable income.
The bill defines key terms such as “covered drug,” “covered entity,” and “direct-to-consumer advertising,” and it applies to advertising disseminated to the general public through channels like television, radio, direct mail, billboards, internet platforms, social media, mobile apps, and similar electronic media. It excludes advertisements placed in journals and other periodicals. The bill takes effect July 1, 2026, and applies to taxable years beginning after December 31, 2025.
HB484 would amend Maryland’s Tax-General Article by adding a new subsection to the corporate income tax modification rules in § 10-305. The effect is to disallow, for Maryland tax purposes, the benefit of federal deductions for direct-to-consumer pharmaceutical advertising expenses tied to covered drugs, thereby increasing taxable income for affected corporations and potentially increasing state revenue. The bill primarily affects pharmaceutical manufacturers, sponsors of prescription drug products, and owners of outsourcing facilities that engage in consumer-facing drug advertising.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, amendments, or formal support/opposition in the available materials. Based on the bill’s sponsors and its policy design, the measure appears to be a targeted tax policy proposal aimed at the pharmaceutical advertising industry rather than a broad tax change. The available record does not show any vote history or committee disposition, so overall sentiment cannot be measured from the supplied context.
The main point of contention is likely the policy choice to single out direct-to-consumer pharmaceutical advertising for unfavorable tax treatment. Supporters would likely view the bill as a way to discourage aggressive drug marketing and recapture tax benefits associated with advertising expenses, while opponents may argue it penalizes lawful marketing, creates an industry-specific tax burden, and could raise compliance questions about what counts as direct-to-consumer advertising or a covered drug. Because no hearing transcript or vote record is available, the specific positions of legislators, industry groups, or public advocates are not documented in the provided materials.